ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Alkermes acquires HDAC inhibitor developer Rodin

by Lisa M. Jarvis
November 23, 2019 | APPEARED IN VOLUME 97, ISSUE 46

 

Alkermes is bolstering its neuroscience pipeline by acquiring Rodin Therapeutics, a biotech firm developing treatments for diseases caused by synaptic dysfunction. Rodin investors will get $100 million up front and up to $850 million in future payments based on the progress of Rodin’s small molecules, which selectively inhibit histone deacetylase (HDAC) complexes. Alkermes noted that it might prioritize the development of preclinical HDAC inhibitors over Rodin’s lead candidate, RDN-929, which is in Phase I studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment